Volume 38 Issue 09
. 
Turn off MathJax
Article Contents
Article Navigation >  Journal of Kunming Medical University  > 2017  >  38(09): 134-139
Wang Chun Long , Han Dan , Wen Liang . Research Progress of Mesothelin in Tumor Diagnosis and Treatment[J]. Journal of Kunming Medical University, 2017, 38(09): 134-139.
Citation: Wang Chun Long , Han Dan , Wen Liang . Research Progress of Mesothelin in Tumor Diagnosis and Treatment[J]. Journal of Kunming Medical University, 2017, 38(09): 134-139.
shu

Research Progress of Mesothelin in Tumor Diagnosis and Treatment

Funds:

基金： 国家自然科学基金资助项目 (81160179, 81160179); 云南省科技厅-昆明医科大学应用基础研究联合专项基金资助助目 (2014FA013, 2009ZC100M);

  • Received Date: 2017-05-11
    Abstract
  • Mesothelin is a cell surface glycoprotein, with little expression in normal tissues, but highly expressed in tumors such as ovarian cancer, pancreatic cancer and malignant mesothelioma.Therefore, mesothelin helps those tumors' early diagnosis, and is related to tumor staging and prognosis.The use of immunotoxin, anti-mesothelin chimeric antibodies, antibody-drug conjugates, chimeric antigen receptor T cells, mesothelin tumor vaccines is progressing towards maturation in the treatment of mesothelin-rich tumors.This article aims to review the research progress of mesothelin in ovarian cancer, pancreatic cancer, malignant mesothelioma diagnosis and treatment.
    • FullText(HTML)
  • loading
    • References(46)
  • [1]
    [1]CHANG K, PASTAN I.Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas and ovarian cancers[J].Cell Biology, 1996, 93 (2) :136-140.[1]CHANG K, PASTAN I.Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas and ovarian cancers[J].Cell Biology, 1996, 93 (2) :136-140.
    [2]
    [2]INGEGERD H, EITEN F, THORSTEN V, et al.Anti-MSLN antibodies and MSLN relate to the clinical state in ovarian carer patients[J].Cancer Epidelmiol Biomarkers Prev, 2008, 17 (6) :1520-1526.[2]INGEGERD H, EITEN F, THORSTEN V, et al.Anti-MSLN antibodies and MSLN relate to the clinical state in ovarian carer patients[J].Cancer Epidelmiol Biomarkers Prev, 2008, 17 (6) :1520-1526.
    [3]
    [3]HASSAN R, BERA T, PASTAN I.Mesothelin:a new target for immunotherapy[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2004, 10 (12 Pt 1) :3937-3942.[3]HASSAN R, BERA T, PASTAN I.Mesothelin:a new target for immunotherapy[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2004, 10 (12 Pt 1) :3937-3942.
    [4]
    [4]BERATK, PASTAN I.Mesothelin is not required for normal mouse development or reproduction[J].Mol Cell Biol, 2000, 20 (8) :2901-2906.[4]BERATK, PASTAN I.Mesothelin is not required for normal mouse development or reproduction[J].Mol Cell Biol, 2000, 20 (8) :2901-2906.
    [5]
    [5]RUMP A, MORIKAWA Y, TANAKA M, et al.Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion[J].J Biol Chem, 2004, 279 (10) :9190-9198.[5]RUMP A, MORIKAWA Y, TANAKA M, et al.Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion[J].J Biol Chem, 2004, 279 (10) :9190-9198.
    [6]
    [6]NORIHISA U, YOICHIRO M, AIROT.MSLN promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast[J].Cancer Cells Mol Cancer Res, 2008, 6 (2) :1-8.[6]NORIHISA U, YOICHIRO M, AIROT.MSLN promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast[J].Cancer Cells Mol Cancer Res, 2008, 6 (2) :1-8.
    [7]
    [7]BHARADWAJ U, MARIN-MULLER C, ZHANG Y, et al.Mesothelin overexpression promotes autocrine IL-6/s IL-6R trans-signaling to stimulate pancreatic cancer cell proliferation[J].Journal of Surgical Research, 2011, 32 (7) :1013-1024.[7]BHARADWAJ U, MARIN-MULLER C, ZHANG Y, et al.Mesothelin overexpression promotes autocrine IL-6/s IL-6R trans-signaling to stimulate pancreatic cancer cell proliferation[J].Journal of Surgical Research, 2011, 32 (7) :1013-1024.
    [8]
    [8]ORDEZ N G.Application of mesothelin immunostaining in tumor diagnosis[J].Am J Surg Pathol, 2003, 27 (11) :1418-1428.[8]ORDEZ N G.Application of mesothelin immunostaining in tumor diagnosis[J].Am J Surg Pathol, 2003, 27 (11) :1418-1428.
    [9]
    [9]ARGANI P, IACOBUZIO-DONAHUE C, RYU B, et al.Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas:identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE) [J].Clin Cancer Res, 2001, 7 (12) :3862-3868.[9]ARGANI P, IACOBUZIO-DONAHUE C, RYU B, et al.Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas:identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE) [J].Clin Cancer Res, 2001, 7 (12) :3862-3868.
    [10]
    [10]HASSAN R, KREITMAN RJ, PASTAN I, WILLINGHAM MC.Localization of mesothelin in epithelial ovarian cancer[J].Appl Immunohistochem Mol Morphol, 2005, 13 (3) :243-247.[10]HASSAN R, KREITMAN RJ, PASTAN I, WILLINGHAM MC.Localization of mesothelin in epithelial ovarian cancer[J].Appl Immunohistochem Mol Morphol, 2005, 13 (3) :243-247.
    [11]
    [11]HOLLEVOET K, BERNARD D, DE G F, et al.Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum[J].Clinical Chemistry, 2009, 55 (7) :1431-1433.[11]HOLLEVOET K, BERNARD D, DE G F, et al.Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum[J].Clinical Chemistry, 2009, 55 (7) :1431-1433.
    [12]
    [12]BOUDVILLE N, PAUL R, ROBINSON B W S, et al.Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening[J].Lung Cancer, 2011, 73 (3) :320-324.[12]BOUDVILLE N, PAUL R, ROBINSON B W S, et al.Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening[J].Lung Cancer, 2011, 73 (3) :320-324.
    [13]
    []
    [14]任玉霞, 吴京芳.卵巢癌患者血清可溶性间皮素相关蛋白的检测及其意义[J].中国实验诊断学, 2014, 18 (1) :86-89.[14]任玉霞, 吴京芳.卵巢癌患者血清可溶性间皮素相关蛋白的检测及其意义[J].中国实验诊断学, 2014, 18 (1) :86-89.
    [15]毕波, 潘逸茹, 周慧敏, 等.卵巢癌患者血清和肿瘤组织CA125和SMRP表达的临床意义[J].国际检验医学杂志, 2015, 36 (1) :22-24.[15]毕波, 潘逸茹, 周慧敏, 等.卵巢癌患者血清和肿瘤组织CA125和SMRP表达的临床意义[J].国际检验医学杂志, 2015, 36 (1) :22-24.
    [16]
    [16]WU XI, LI D, LIU L, et al.Serum soluble mesothelin-related peptide (SMRP) :A potential diagnostic and monitoring marker for epithelial ovarian cancer[J].Arch Gynecol Obstet, 2014, 289 (6) :1309-1402.[16]WU XI, LI D, LIU L, et al.Serum soluble mesothelin-related peptide (SMRP) :A potential diagnostic and monitoring marker for epithelial ovarian cancer[J].Arch Gynecol Obstet, 2014, 289 (6) :1309-1402.
    [17]邱振华, 王茂生, 杨长福, 等.卵巢癌患者血清糖链抗原125联合人附睾上皮分泌蛋白4及可溶性间皮素相关肽测定临床价值[J].中华实用诊断与治疗杂志, 2015, 29 (6) :583-585.[17]邱振华, 王茂生, 杨长福, 等.卵巢癌患者血清糖链抗原125联合人附睾上皮分泌蛋白4及可溶性间皮素相关肽测定临床价值[J].中华实用诊断与治疗杂志, 2015, 29 (6) :583-585.
    [18]
    [18]IBRAHIM M, BAHAA A, IBRAHIM A, et al.Evaluation of serum mesothelin in malignant and benign ovarian masses[J].Arch Gynecol Obstet, 2014, 290 (1) :107-113.[18]IBRAHIM M, BAHAA A, IBRAHIM A, et al.Evaluation of serum mesothelin in malignant and benign ovarian masses[J].Arch Gynecol Obstet, 2014, 290 (1) :107-113.
    [19]
    [19]HELLSTROM I, RAYCRAFT J, KANAN S, et al.mesothelin variant 1 is released from tumor cells as a diagnostic marker[J].Cancer Epidemiol Biomarkers Prev, 2006, 15 (5) :1014-1020.[19]HELLSTROM I, RAYCRAFT J, KANAN S, et al.mesothelin variant 1 is released from tumor cells as a diagnostic marker[J].Cancer Epidemiol Biomarkers Prev, 2006, 15 (5) :1014-1020.
    [20]
    [20]CAO D, JI H, RONNETT BM.Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary[J].International Journal of Gynecological Pathology, 2005, 24 (24) :67-72.[20]CAO D, JI H, RONNETT BM.Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary[J].International Journal of Gynecological Pathology, 2005, 24 (24) :67-72.
    [21]杨光.间皮素在胰腺癌组织及周围淋巴结中的表达及临床意义[D].沈阳:中国医科大学 (硕士论文) , 2008.[21]杨光.间皮素在胰腺癌组织及周围淋巴结中的表达及临床意义[D].沈阳:中国医科大学 (硕士论文) , 2008.
    [22]杜以龙.胰腺癌组织中PSCA、Mesothelin的表达及其临床意义[D].苏州:苏州大学 (硕士论文) , 2009.[22]杜以龙.胰腺癌组织中PSCA、Mesothelin的表达及其临床意义[D].苏州:苏州大学 (硕士论文) , 2009.
    [23]
    [23]JHALA N, JHALA D, VICKERS S M, et al.Biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates[J].American Journal of Clinical Pathology, 2006, 126 (4) :572-579.[23]JHALA N, JHALA D, VICKERS S M, et al.Biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates[J].American Journal of Clinical Pathology, 2006, 126 (4) :572-579.
    [24]
    [24]DIM DC, FENG JIANG, QI Q, et al.The usefulness of S100P, mesothelin, fascin, prostate stem cell antigen, and14-3-3 sigma in diagnosing pancreatic adenocarcinoma in cytological specimens obtained by endoscopic ultrasound guided fine-needle aspiration[J].Diagnostic Cytopathology, 2014, 42 (3) :193-199.[24]DIM DC, FENG JIANG, QI Q, et al.The usefulness of S100P, mesothelin, fascin, prostate stem cell antigen, and14-3-3 sigma in diagnosing pancreatic adenocarcinoma in cytological specimens obtained by endoscopic ultrasound guided fine-needle aspiration[J].Diagnostic Cytopathology, 2014, 42 (3) :193-199.
    [25]
    [25]ROBINSON BW, CREANEY J, LAKE R, et al.Mesothelin-family proteins and diagnosis of mesothelioma[J].Lancet, 2003, 362 (9396) :1612-1616.[25]ROBINSON BW, CREANEY J, LAKE R, et al.Mesothelin-family proteins and diagnosis of mesothelioma[J].Lancet, 2003, 362 (9396) :1612-1616.
    [26]
    [26]HOLLEVOET K, NACKAERTS K, GOSSELIN R, et al.Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma[J].Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer, 2011, 6 (11) :1930-1937.[26]HOLLEVOET K, NACKAERTS K, GOSSELIN R, et al.Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma[J].Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer, 2011, 6 (11) :1930-1937.
    [27]
    [27]BLANQUART C, GUEUGNON F, NGUYEN J M, et al.CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions[J].Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer, 2012, 7 (7) :883-889.[27]BLANQUART C, GUEUGNON F, NGUYEN J M, et al.CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions[J].Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer, 2012, 7 (7) :883-889.
    [28]
    [28]HOOPER CE, MORLEY AJ, VIRGO P, et al.A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions[J].European Respiratory Journal, 2013, 41 (1) :18-24.[28]HOOPER CE, MORLEY AJ, VIRGO P, et al.A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions[J].European Respiratory Journal, 2013, 41 (1) :18-24.
    [29]
    [29]CREANEY J, DICK I M, DARE H, et al.Does CA125binding to mesothelin impact the detection of malignant mesothelioma[J].Lung Cancer, 2013, 80 (1) :39-44.[29]CREANEY J, DICK I M, DARE H, et al.Does CA125binding to mesothelin impact the detection of malignant mesothelioma[J].Lung Cancer, 2013, 80 (1) :39-44.
    [30]
    [30]FILIBERTI R, PARODI S, LIBENER R, et al.Diagnostic value of mesothelin in pleural fluids:comparison with CYFRA 21-1 and CEA[J].Medical Oncology, 2013, 30 (2) :1-9.[30]FILIBERTI R, PARODI S, LIBENER R, et al.Diagnostic value of mesothelin in pleural fluids:comparison with CYFRA 21-1 and CEA[J].Medical Oncology, 2013, 30 (2) :1-9.
    [31]
    [31]MULEY T, DIENEMANN H, HERTH F J, et al.Combination of mesothelin and Csignificantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer[J].Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer, 2013, 8 (7) :947-951.[31]MULEY T, DIENEMANN H, HERTH F J, et al.Combination of mesothelin and Csignificantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer[J].Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer, 2013, 8 (7) :947-951.
    [32]
    [32]PASTAN I, HASSAN R.Discovery of mesothelin and exploiting it as a target for immunotherapy[J].Cancer Research, 2014, 74 (11) :2907-2912.[32]PASTAN I, HASSAN R.Discovery of mesothelin and exploiting it as a target for immunotherapy[J].Cancer Research, 2014, 74 (11) :2907-2912.
    [33]
    [33]ZHANG Y, XIANG L, HASSAN R, et al.Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2006, 12 (15) :4695-4701.[33]ZHANG Y, XIANG L, HASSAN R, et al.Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2006, 12 (15) :4695-4701.
    [34]
    [34]HASSAN R, SHARON E, SCHULER B, et al.Antitumor activity of SS1P with pemetrexed and cisplatin for front-line treatment of pleural mesothelioma and utility of serum mesothelin as a marker of tumor response.[J].Journal of Clinical Oncology, 2011, 29 (15) :2696-2696.[34]HASSAN R, SHARON E, SCHULER B, et al.Antitumor activity of SS1P with pemetrexed and cisplatin for front-line treatment of pleural mesothelioma and utility of serum mesothelin as a marker of tumor response.[J].Journal of Clinical Oncology, 2011, 29 (15) :2696-2696.
    [35]
    [35]HASSAN R, WILLIAMS-GOULD J, WATSON T, et al.Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1[J].Forensic Science International Genetics Supplement, 2004, 10 (1) :16-18.[35]HASSAN R, WILLIAMS-GOULD J, WATSON T, et al.Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1[J].Forensic Science International Genetics Supplement, 2004, 10 (1) :16-18.
    [36]
    [36]HASSAN R, MILLER A C, SHARON E, et al.Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression[J].Science Translational Medicine, 2013, 5 (208) :888-891.[36]HASSAN R, MILLER A C, SHARON E, et al.Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression[J].Science Translational Medicine, 2013, 5 (208) :888-891.
    [37]
    [37]ZHANG J, KHANNA S, JIANG Q, et al.Efficacy of anti-mesothelin immunotoxin RG7787 plus nab-paclitaxel against mesothelioma patient derived xenografts and mesothelin as a biomarker of tumor response[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2016, 23 (6) :1564-1574.[37]ZHANG J, KHANNA S, JIANG Q, et al.Efficacy of anti-mesothelin immunotoxin RG7787 plus nab-paclitaxel against mesothelioma patient derived xenografts and mesothelin as a biomarker of tumor response[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2016, 23 (6) :1564-1574.
    [38]
    [38]HASSAN R, EBEL W, ROUTHIER E L, et al.Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin[J].Cancer Immunity A Journal of the Academy of Cancer Immunology, 2006, 19 (7) :20-20.[38]HASSAN R, EBEL W, ROUTHIER E L, et al.Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin[J].Cancer Immunity A Journal of the Academy of Cancer Immunology, 2006, 19 (7) :20-20.
    [39]
    [39]HASSAN R, COHEN S J, PHILLIPS M, et al.Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers[J].Clinical Cancer Research, 2010, 16 (24) :6132-6138.[39]HASSAN R, COHEN S J, PHILLIPS M, et al.Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers[J].Clinical Cancer Research, 2010, 16 (24) :6132-6138.
    [40]
    [40] HASSAN R, KINDLER H L, JAHAN T, et al.Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2014, 20 (23) :5927-5936.[40]HASSAN R, KINDLER H L, JAHAN T, et al.Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2014, 20 (23) :5927-5936.
    [41]
    [41]HASSAN R, KINDLER H L, JAHAN T, et al.Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2014, 20 (23) :5927-5936.[41]HASSAN R, KINDLER H L, JAHAN T, et al.Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2014, 20 (23) :5927-5936.
    [42]
    [42]BENDELL J, BLUMENSCHEIN G, ZINNER R, et al.Abstract LB-291:First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC) , BAY 94-9343, in patients with advanced solid tumors[J].Cancer Research, 2013, 73 (8 Supplement) :291.[42]BENDELL J, BLUMENSCHEIN G, ZINNER R, et al.Abstract LB-291:First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC) , BAY 94-9343, in patients with advanced solid tumors[J].Cancer Research, 2013, 73 (8 Supplement) :291.
    [43]
    [43]BROCKER T, KARJALAINEN K.Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes[J].Journal of Experimental Medicine, 1995, 181 (5) :1653-1659.[43]BROCKER T, KARJALAINEN K.Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes[J].Journal of Experimental Medicine, 1995, 181 (5) :1653-1659.
    [44]
    [44]KERSHAW M H, WESTWOOD J A, PARKER L L, et al.A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2006, 12 (20 Pt 1) :6106-6115.[44]KERSHAW M H, WESTWOOD J A, PARKER L L, et al.A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2006, 12 (20 Pt 1) :6106-6115.
    [45]
    [45]LAMERS C H, WILLEMSEN R, VAN ELZAKKER P, et al.Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells[J].Blood, 2011, 117 (1) :72-82.[45]LAMERS C H, WILLEMSEN R, VAN ELZAKKER P, et al.Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells[J].Blood, 2011, 117 (1) :72-82.
    [46]
    [46]LE D T, BROCKSTEDT D G, NIR-PAZ R, et al.A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers:phase I studies of safety and immune induction[J].Clinical Cancer Research, 2012, 18 (3) :858-868.[46]LE D T, BROCKSTEDT D G, NIR-PAZ R, et al.A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers:phase I studies of safety and immune induction[J].Clinical Cancer Research, 2012, 18 (3) :858-868.
    • Relative Articles(20)

  • Relative Articles

    [1] Lei ZHU, Ruixue LI, Changlei BAO, Chenchen HUANG, Shuxin LIANG, Zhenlin ZHAO, Hong ZHU. Effect of MSC-exo，a New Cell Delivery Tool，on Gene Delivery and Proliferation of Pancreatic Cancer. Journal of Kunming Medical University, 2024, 45(2): 39-48.  doi: 10.12259/j.issn.2095-610X.S20240206
    [2] Qingbin ZENG, Rong Xu, Wenzhi DONG, Zhijian CHEN, Weiran LIAO, Kui LONG. Expression of Zinc Finger Transcription Factor Sall4 In Pancreatic Cancer and Its Impact on Cell Invasion and Migration. Journal of Kunming Medical University, 2024, 46(): 1-7.
    [3] Runlin FENG, Zongqi DENG, Mengyao WU, Yunna WANG, Yu WANG, Guilan LIU. GJB4 Gene Expression in Relation to Clinical and Pathological Features of Pancreatic Cancer Patients. Journal of Kunming Medical University, 2024, 45(8): 1-9.
    [4] Lizhu ZHAO, Ying DONG, Yue DENG, Lihua YANG. Correlation between Epithelial Cell Related Genes and Prognosis of Patients with Ovarian Cancer based on Single Cell Sequencing. Journal of Kunming Medical University, 2024, 45(4): 9-16.  doi: 10.12259/j.issn.2095-610X.S20240402
    [5] Xingfen WANG, Yue DENG, Lihua YANG. Construction of Lipid Metabolism-Related Gene Prognostic Model and Immunoinfiltration Analysis of Ovarian Cancer. Journal of Kunming Medical University, 2024, 45(4): 17-25.  doi: 10.12259/j.issn.2095-610X.S20240403
    [6] Sijia LIU, Yaying YANG, Chao PENG, Yamin LI. Application of Contrast-enhanced CT and MRI in Preoperative TNM Staging of Pancreatic Cancer. Journal of Kunming Medical University, 2023, 44(6): 107-112.  doi: 10.12259/j.issn.2095-610X.S20230628
    [7] Yangyang LIAN, Hongping YUE, Ya DUAN, Hongwen HU, Fang LUO. The Role of miRNA-15a/16 in Regulating Bmi-1 Protein in Ovarian Cancer Resistance to Cisplatin Chemotherapy. Journal of Kunming Medical University, 2023, 44(12): 25-31.  doi: 10.12259/j.issn.2095-610X.S20231204
    [8] Xiaoyan YANG, Chunguang HAO, Zhijian ZHANG. Mechanisms of Progesterone on Proliferation and Migration of Human Ovarian Cancer Cells via HOXA9. Journal of Kunming Medical University, 2022, 43(10): 35-42.  doi: 10.12259/j.issn.2095-610X.S20221022
    [9] Lixiu XU, TUERXUN Meiliban, YAKUFU Kereman. Studies on Cisplatin Resistance of miR-181a in Ovarian Cancer Cells. Journal of Kunming Medical University, 2022, 43(1): 20-25.  doi: 10.12259/j.issn.2095-610X.S20220131
    [10] Yue DENG, Dan ZOU, Abdelkerim Barh TOUNA, Lihua YANG. Expression of PDE4D Gene in Ovarian Cancer Based on Oncomine and the Regulation of Sanguinarine. Journal of Kunming Medical University, 2022, 43(3): 1-6.  doi: 10.12259/j.issn.2095-610X.S20220303
    [11] Jing-hui LI, Ming ZHU, Hai QU, Qiu-yu LI, Yu-juan WU, He-ying YANG, Yu-zhu WANG, Yan-ping LI. miR-490-3p Suppresses EMT of SW1990 Pancreatic Cancer Cells. Journal of Kunming Medical University, 2021, 42(3): 10-17.  doi: 10.12259/j.issn.2095-610X.S20210305
    [12] Li Fei Fei , Hao Jin Gang . . Journal of Kunming Medical University, 2020, 41(04): 69-73.
    [13] Shen Hong , Wang Xiu Yun , Xu Hui Qiong , Liu Xia . Analysis of Clinicopathological Features of 274 Cases of Pancreatic Cancer and Risk Factors Affecting Prognosis. Journal of Kunming Medical University, 2019, 40(03): 97-101.
    [14] Hu Yu Chong , Lu Jing Kun , Cui Meng Yao . . Journal of Kunming Medical University, 2017, 38(03): 27-30.
    [15] Yang Ke , Dan Zu Jian , Zhou Qiong Hua , Wang Jun Feng . Relationship between Soluble Cytokine Receptors, Matrix Metalloproteinases and Pancreatic Cancer. Journal of Kunming Medical University, 2017, 38(01): 99-102.
    [16] Lei Xue Fen . . Journal of Kunming Medical University,
    [17] Han Dan . . Journal of Kunming Medical University,
    [18] Yang Li Hua . . Journal of Kunming Medical University,
    [19] . Diagnosis and Treatment of 11 Patients with Malignant Peritoneal Mesothelioma. Journal of Kunming Medical University,
    [20] . Inhibition of Canonical Wnt Signaling Pathway in Pancreatic Cancer by Interfering CXCR4 in Vitro. Journal of Kunming Medical University,
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (3143) PDF downloads(178) Cited by()
    Proportional views
    Related

    Copyright © 《昆明医科大学学报》编辑部  滇ICP备00000000号-0

    Publishing: 昆明医科大学学报编辑部

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return